AGP Executive Report
Last update: 4 hours agoBiotech Research: Jersey City-based Celltrion will present new analyses of its injectable infliximab treatment for Crohn’s disease and ulcerative colitis at a national meeting, including findings on outcomes after switching from IV treatment. Rahway-based Merck reported one-year trial results for an experimental diabetic macular edema drug; it matched ranibizumab on the study’s main vision measure but did not outperform it. Research Talent: Rutgers’ Brain Health Institute has recruited a prominent autism expert, while a new biotech ecosystem is taking shape around the New Brunswick Innovation Hub. Infrastructure Tech: Veolia completed a $58 million wastewater treatment plant in Plainsboro, and data center operator Guardian Data opened a 42,000-square-foot facility in Moonachie.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
